Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common non-traumatic cause of disability in young adults. Recent research shows that vascular disease risk factors (VDRFs) such as obesity, smoking, hyperlipidemia, hypertension, type II diabetes mellitus, and metabolic syndrome, can influence MS on its onset, disease activity, progression, and resultant disability. This review evaluates the current knowledge on the role of VDRFs on outcomes among people with MS (PwMS) and shows that while VDRF prevalence may or may not be higher among PwMS compared with the general population, its presence can influence MS in myriad ways. Management of VDRFs through early detection and treatment may be a promising approach to improving outcomes in PwMS.
Multiple sclerosis, smoking, obesity, dyslipidemia, hypertension, type II diabetes, metabolic syndrome
No funding was received in the publication of this article. Meena Kannan and Vijayshree Yadav have no relevant conflicts of interest to declare.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Vijayshree Yadav, Mail Code L226, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, US. E: email@example.com
This article is published under the Creative Commons Attribution Noncommercial License, which
permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.
Share this Article
Related Content In Multiple Sclerosis
What Fluid Biomarkers Tell Us at Different Stages of Multiple Sclerosis
touchREVIEWS in Neurology. 2024;20(1):Online ahead of journal publication
Multiple sclerosis (MS) is a complex disease that can pose significant challenges in diagnosis, monitoring and treatment. Over the years, the quest for more precise and accessible diagnostic tools has led to the exploration of different fluid biomarkers in cerebrospinal fluid (CSF) or serum. Fluid biomarkers can offer insights into the diagnosis, prognosis and treatment […]
Foreword: touchREVIEWS in Neurology, Volume 19, Issue 2, 2023
In the latest edition of touchREVIEWS in Neurology, we are pleased to present a collection of insightful articles that highlight the current landscape and future directions in neurological research and treatment. Firstly, Rajvinder Karda opens this issue with a compelling expert interview on the future of SCN1A gene-targeting research for the treatment of Dravet syndrome. […]
Paradoxical Tumefactive Worsening of Multiple Sclerosis After Natalizumab Initiation: A Case Report
touchREVIEWS in Neurology. 2023;19(2):19-22
Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination and neurodegeneration. Natalizumab is a widely used anti-α4 integrin inhibitor for treating highly active MS. In the pivotal trials of natalizumab for MS, the SENTINEL and AFFIRM trials, natalizumab was established to reduce the rate of clinical relapses and […]